Crystallizing the Relationship Between Patents, Polymorphs and Psilocybin
Compass Pathways was granted a patent for what they claim to be a newly discovered crystalline form of psilocybin. This patent would allow Compass to exclude others from benefitting from the use of that crystalline form. That patent was challenged in court due to ambiguous scientific jargon and, more critically, because Polymorph A is not a new polymorph at all. We explain what crystal polymorphs are, why finding new polymorphs is significant, and why scientists are able to claim this new crystal structure not new at all.
The original article can be found at: Terpenes and Testing Magazine
Related Articles
As different cannabis products have differing potency levels, knowing the potency of a product is important for determining the correct dosage. Currently, chromatography is used for potency testing of cannabis products. We teamed up with Agilent to show that FTIR spectroscopy can also be used to further enhance these testing processes.
